A citation-based method for searching scientific literature

Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver, Sarah H Lockie, David L Smiley, Vasily Gelfanov, Bin Yang, Susanna Hofmann, Dennis Bruemmer, Daniel J Drucker, Paul T Pfluger, Diego Perez-Tilve, Jaswant Gidda, Louis Vignati, Lianshan Zhang, Jonathan B Hauptman, Michele Lau, Mathieu Brecheisen, Sabine Uhles, William Riboulet, Emmanuelle Hainaut, Elena Sebokova, Karin Conde-Knape, Anish Konkar, Richard D DiMarchi, Matthias H Tschöp. Sci Transl Med 2013
Times Cited: 321



Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni, Hiroshi Hiai, Wataru Mizunoya, Tohru Fushiki, Jens Juul Holst, Mitsuhiro Makino, Akira Tashita, Yukari Kobara, Yoshiharu Tsubamoto, Takayoshi Jinnouchi, Takahito Jomori, Yutaka Seino. Nat Med 2002
Times Cited: 633




List of shared articles



Times cited

Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Orla R M Woodward, Fiona M Gribble, Frank Reimann, Jo E Lewis. J Physiol 2022
4

Glucagon-like peptide-1 in diabetes care: Can glycaemic control be achieved without nausea and vomiting?
Tito Borner, Ian C Tinsley, Robert P Doyle, Matthew R Hayes, Bart C De Jonghe. Br J Pharmacol 2022
5

The incretin/glucagon system as a target for pharmacotherapy of obesity.
Stefano Del Prato, Baptist Gallwitz, Jens Juul Holst, Juris J Meier. Obes Rev 2022
3

GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Ashok Mayendraraj, Mette M Rosenkilde, Lærke S Gasbjerg. Peptides 2022
1

The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases.
Tingkai Chen, Tianyu Sun, Yaoyao Bian, Yuqiong Pei, Feng Feng, Heng Chi, Yuan Li, Xu Tang, Shenghu Sang, Chenxi Du,[...]. J Med Chem 2022
0

Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes.
Qiming Tan, Seun E Akindehin, Camila E Orsso, Richelle C Waldner, Richard D DiMarchi, Timo D Müller, Andrea M Haqq. Front Endocrinol (Lausanne) 2022
2

The Enteroendocrine System in Obesity.
Emily L Miedzybrodzka, Frank Reimann, Fiona M Gribble. Handb Exp Pharmacol 2022
1

Regulation of feeding and therapeutic application of bioactive peptides.
Hiroaki Ueno, Weidong Zhang, Masamitsu Nakazato. Pharmacol Ther 2022
0

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Patrick J Knerr, Stephanie A Mowery, Jonathan D Douros, Bhavesh Premdjee, Karina Rahr Hjøllund, Yantao He, Ann Maria Kruse Hansen, Anette K Olsen, Diego Perez-Tilve, Richard D DiMarchi,[...]. Mol Metab 2022
0




Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists.
Aaron Novikoff, Shannon L O'Brien, Miriam Bernecker, Gerald Grandl, Maximilian Kleinert, Patrick J Knerr, Kerstin Stemmer, Martin Klingenspor, Anja Zeigerer, Richard DiMarchi,[...]. Mol Metab 2021
14

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling.
Qian Zhang, Challa Tenagne Delessa, Robert Augustin, Mostafa Bakhti, Gustav Colldén, Daniel J Drucker, Annette Feuchtinger, Cristina Garcia Caceres, Gerald Grandl, Alexandra Harger,[...]. Cell Metab 2021
41

GIPR Signaling in Immune Cells Maintains Metabolically Beneficial Type 2 Immune Responses in the White Fat From Obese Mice.
Irina Efimova, Inbar Steinberg, Isabel Zvibel, Anat Neumann, Dana Fernanda Mantelmacher, Daniel J Drucker, Sigal Fishman, Chen Varol. Front Immunol 2021
2

Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion.
Van B Lu, Fiona M Gribble, Frank Reimann. Nutrients 2021
13

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
Ricardo J Samms, Michael E Christe, Kyla Al Collins, Valentina Pirro, Brian A Droz, Adrienne K Holland, Jessica L Friedrich, Samantha Wojnicki, Debra L Konkol, Richard Cosgrove,[...]. J Clin Invest 2021
19

GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.
Shu-Chen Lu, Michelle Chen, Larissa Atangan, Elizabeth A Killion, Renee Komorowski, Yuan Cheng, Chawita Netirojjanakul, James R Falsey, Marina Stolina, Denise Dwyer,[...]. Cell Rep Med 2021
8

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea.
Matthew R Hayes, Tito Borner, Bart C De Jonghe. Diabetes 2021
4


GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.
Ricardo J Samms, Kyle W Sloop, Fiona M Gribble, Frank Reimann, Alice E Adriaenssens. Diabetes 2021
6

Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.
Michael A Nauck, Jakob Wefers, Juris J Meier. Lancet Diabetes Endocrinol 2021
18


Incretins in obesity and diabetes.
Chee W Chia, Josephine M Egan. Ann N Y Acad Sci 2020
32

Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists?
Elizabeth A Killion, Shu-Chen Lu, Madeline Fort, Yuichiro Yamada, Murielle M Véniant, David J Lloyd. Endocr Rev 2020
25

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
Rie Suzuki, Giles A Brown, John A Christopher, Conor C G Scully, Miles Congreve. J Med Chem 2020
13

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease.
Sebastian M Heimbürger, Natasha C Bergmann, Robert Augustin, Lærke S Gasbjerg, Mikkel B Christensen, Filip K Knop. Peptides 2020
9




Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes.
William G Tharp, Dhananjay Gupta, Olga Sideleva, Carolyn F Deacon, Jens J Holst, Dariush Elahi, Richard E Pratley. Diabetes 2020
4


Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates.
Patrick J Knerr, Stephanie A Mowery, Brian Finan, Diego Perez-Tilve, Matthias H Tschöp, Richard D DiMarchi. Peptides 2020
20

Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review.
Maria Buur Nordskov Gabe, Wijnand J C van der Velden, Florent Xavier Smit, Lærke Smidt Gasbjerg, Mette Marie Rosenkilde. Peptides 2020
14

Cardiovascular biology of the GIP receptor.
Amanda A Greenwell, Jadin J Chahade, John R Ussher. Peptides 2020
5

Recent advances of GIP and future horizons.
Jens Juul Holst, Mette Marie Rosenkilde. Peptides 2020
12

Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor.
Xiaoshan Min, Junming Yie, Jinghong Wang, Ben C Chung, Ching-Shin Huang, Haoda Xu, Jie Yang, Liying Deng, Joanne Lin, Qing Chen,[...]. MAbs 2020
5